Browsing College of Engineering by Publisher "BioMed Central Ltd"
Now showing items 1-6 of 6
-
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired
( BioMed Central Ltd , 2023 , Article Review)Cancer is still the leading cause of death globally. The approval of the therapeutic use of monoclonal antibodies against immune checkpoint molecules, notably those that target the proteins PD-1 and PD-L1, has changed the ... -
Designing a reference architecture for health information systems
( BioMed Central Ltd , 2021 , Article)Background: Healthcare relies on health information systems (HISs) to support the care and receive reimbursement for the care provided. Healthcare providers experience many problems with their HISs due to improper architecture ... -
Exome sequencing of glioblastoma-derived cancer stem cells reveals rare clinically relevant frameshift deletion in MLLT1 gene
( BioMed Central Ltd , 2022 , Article)Background: Glioblastoma multiforme (GBM) is a heterogeneous CNS neoplasm which causes significant morbidity and mortality. One reason for the poor prognostic outcome of GBM is attributed to the presence of cancer stem ... -
Genomic landscape of prominent XDR Acinetobacter clonal complexes from Dhaka, Bangladesh
( BioMed Central Ltd , 2022 , Article)Background: Acinetobacter calcoaceticus-A. baumannii (ACB) complex pathogens are known for their prevalence in nosocomial infections and extensive antimicrobial resistance (AMR) capabilities. While genomic studies worldwide ... -
p53 signaling in cancer progression and therapy
( BioMed Central Ltd , 2021 , Article)The p53 protein is a transcription factor known as the "guardian of the genome" because of its critical function in preserving genomic integrity. The TP53 gene is mutated in approximately half of all human malignancies, ... -
Potential of antibody-drug conjugates (ADCs) for cancer therapy
( BioMed Central Ltd , 2022 , Article Review)The primary purpose of ADCs is to increase the efficacy of anticancer medications by minimizing systemic drug distribution and targeting specific cells. Antibody conjugates (ADCs) have changed the way cancer is treated. ...